16/04/2018 15:49:13

MYnd Analytics and Arcadian Telepsychiatry Services Announce Launch of School-Based Telepsychiatry Program Designed to Provide Youths with School-Based  Access to Mental Health Services

MISSION VIEJO, Calif., April 16, 2018 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. (NASDAQ:MYND), a market leader in improving the delivery of mental health through the combination of telemedicine and data analytics/augmented intelligence, today announced that its wholly owned subsidiary, Arcadian Telepsychiatry Services LLC, has launched a new program to offer, through its network of Providers, youths in rural, suburban and urban markets with school-based access to telepsychiatry, teletherapy and other mental health services. Telepsychiatry involves the use of video conferencing equipment to conduct real time mental health consultations between a clinician and a patient. This program is designed to benefit children and teenagers across the country, especially those with limited access to mental health services.

Robert Plotkin, CEO and Founder of Arcadian, stated, “Two-thirds of US primary care physicians report not having adequate access to psychiatric care for their patients and over eighty-nine million Americans live in federally designated Mental Health Professional Shortage Areas (MHPSA). Sadly, many of those affected by lack of access to proper care are children and teenagers. It is often teachers and guidance counselors that are the first to identify at-risk youths, and yet, the schools are often unable to provide and cannot even refer the necessary mental health services. This is due to a lack of local providers, lack of school resources and a host of other reasons.  Providing youths with appropriate mental health services must be a national priority, because when left unaddressed, these children and teenagers often fall between the cracks of society, and may even turn to drugs or violence. We believe our program will improve and may even save lives through early intervention and providing children and teenagers direct access to trained professionals within the familiar, convenient, private and safe environment of their school. I am happy to report we are in active discussions with a number of schools and community programs across the country that recognize the value of this offering.”

George Carpenter, CEO of MYnd Analytics, commented, “By combining our tele-medicine platform with MYnd’s Peer report, we can reduce trial and error prescribing in mental health, which is a leading reason many of these children are non-compliant with medications and/or drop out of therapy programs.  In fact, the PEER report has been clinically shown to improve outcomes in many of the most common mental health issues, including depression and anxiety.  In the U.S. alone, the 2016 National Survey of Children’s Health (NSCH) estimates 6.1 million or 9.4% of all children in the U.S. have been diagnosed with ADHD, and nearly 2 of 3 children with current ADHD had at least one other mental, emotional, or behavioral disorder.  We believe this new combined offering will have a significant social impact in schools and communities around the country.”

About MYnd Analytics

MYnd Analytics, Inc. (www.myndanalytics.com) is a predictive analytics company that has developed a decision support tool to help physicians reduce trial and error treatment in mental health and provide more personalized care to patients. The Company’s Psychiatric EEG Evaluation Registry, or PEER Online, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the Company’s original physician-developed database, there are now more than 39,000 outcomes for over 11,000 unique patients in the PEER registry. The goal of PEER Online is to provide objective, personalized data to assist physicians in the selection of appropriate medications.

About Arcadian

Arcadian Telepsychiatry Services LLC manages a suite of services including telepsychiatry, teletherapy, digital patient screening, curbside consultation, on-demand services, and scheduled encounters for all age groups. Arcadian utilizes patient engagement and re-engagement strategies so that care is effectively completed, helping to comfortably move inpatient care to outpatient, assisting patients in readjusting to their life routine, as well as reducing wait times for mental health treatment. Arcadian’s customer base includes major health plans, health systems, and community-based organizations.

Forward-looking Statements

Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties, such as statements regarding market developments, new products and growth strategies, Arcadian's ability to reduce patient suffering through increased access to care, Arcadian's ability to use MYnd’s data analytics capabilities to successfully reduce trial and error prescribing, advantages offered by telemedicine, the ability of MYnd’s and Arcadian's products to successfully target objectivity and increased efficiency in the treatment of depression and other mental health and psychiatric illnesses, as well as those risks and uncertainties set forth in MYnd's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.

To read more about the benefits of this patented technology for patients, physicians and payers, please visit: www.myndanalytics.com.

Contact:

Crescendo Communications, LLC

Tel: +1 (212) 671-1020

Email: mynd@crescendo-ir.com

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
15 Oct
DANSKE
Stop dog for helvede dine sindsyge indlæg. Det er brugere som dig der fuldkommen smadrer det her for..
27
11 Oct
OMXC25
... og det betyder som regel, at det er sidste ben i nedturen, før en pause, eller en positiv modrea..
24
12 Oct
DANSKE
Ole Andersen havde ansat 5 kanibaler til at ryde op efter hvidvasskandalen. I har nu fast arbejde, t..
21
13 Oct
PNDORA
Carnegie's seneste analyse gav lidt medvind til pandora, men det var slet ikke meningen, idet alle j..
20
10 Oct
DANSKE
TYVERI FOR 100 MILLIONER - DANSKE BANKS ANSVAR?Igår kom en historie om en kvinde, der systematisk ig..
18
14 Oct
DANSKE
En korruptionsbekæmper skudt i Moskva, er nu også blevet Danske Banks skyld, hvor ussel kan denne p..
17
12 Oct
DANSKE
Der er noget ejendommeligt ved danmarkshistoriens formentlig største pengeinstitutskandale: Formentl..
15
13 Oct
CHEMM
@Tommy, Du stiller et meget relevant spørgsmål, men først vil jeg korrigere lidt på dit P/E. Som inv..
14
12 Oct
VELO
Blot til orientering. Kursudvikling i Veloxis vs. øvrige danske biotek/medico seneste måned: Velo..
14
15 Oct
OMXC25
Jeg har tænkt over den seneste uges udvikling. Min globale-US-dollars-allokerings-model (GUSDAM) vis..
13

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Matinas BioPharma Appoints Global Pharmaceutical Drug Development Industry Leader Theresa Matkovits, Ph.D., Chief Development Officer; Further Expands Manufacturing and Clinical Development Team
2
EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg
3
JCDecaux: Update on JCDecaux's proposed acquisition of APN Outdoor in Australia
4
Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research
5
ACACIA PHARMA PROVIDES FURTHER UPDATE ON FDA REGULATORY REVIEW OF BARHEMSYS(TM)

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 October 2018 01:38:27
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20181005.3 - EUROWEB1 - 2018-10-16 02:38:27 - 2018-10-16 01:38:27 - 1000 - Website: OKAY